These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 16197360)

  • 1. Olanzapine: a critical review of recent literature.
    Buckley PF
    Expert Opin Pharmacother; 2005 Oct; 6(12):2077-89. PubMed ID: 16197360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olanzapine in schizophrenia and affective disorders.
    Undurraga J; Vieta E; Tohen M; Colom F
    Drug Saf; 2012 Dec; 35(12):1185-6; author reply 1186. PubMed ID: 23137154
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatological side effects of olanzapine.
    Varghese ST; Balhara YP; Shyamsunder S; Mondal A
    Indian J Med Sci; 2005 Jul; 59(7):320-1. PubMed ID: 16062020
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Baldessarini RJ
    Drug Saf; 2012 Dec; 35(12):1183; author reply 1183-4. PubMed ID: 23137152
    [No Abstract]   [Full Text] [Related]  

  • 6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol.
    Duncan E; Szilagyi S; Schwartz M; Kunzova A; Negi S; Efferen T; Peselow E; Chakravorty S; Stephanides M; Harmon J; Bugarski-Kirola D; Gonzenbach S; Rotrosen J
    Psychiatry Res; 2003 Aug; 120(1):1-12. PubMed ID: 14500109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.
    Hargreaves WA; Gibson PJ
    CNS Drugs; 2005; 19(5):393-410. PubMed ID: 15907151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
    Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
    J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Compliance with treatment in schizophrenia and mood disorders].
    Sorvaniemi M; Kampman O
    Duodecim; 2000; 116(3):277-84. PubMed ID: 11764451
    [No Abstract]   [Full Text] [Related]  

  • 13. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being.
    Kluge M; Wehmeier PM; Dittmann RW; Langer F; Czekalla J; Lehmann M; Kessler FH; Beyenburg S; Naber D
    Pharmacopsychiatry; 2005 Jan; 38(1):6-12. PubMed ID: 15706459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in schizophrenic patients.
    Bobes J; Garcia-Portilla MP; Bascaran MT; Saiz PA; Bousoño M
    Dialogues Clin Neurosci; 2007; 9(2):215-26. PubMed ID: 17726919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
    Ye W; Fujikoshi S; Nakahara N; Takahashi M; Ascher-Svanum H; Ohmori T
    Psychiatry Clin Neurosci; 2012 Jun; 66(4):313-21. PubMed ID: 22624736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine treatment of residual positive and negative symptoms.
    Buchanan RW; Ball MP; Weiner E; Kirkpatrick B; Gold JM; McMahon RP; Carpenter WT
    Am J Psychiatry; 2005 Jan; 162(1):124-9. PubMed ID: 15625210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
    Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
    J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methodological concerns in a trial of ziprasidone and olanzapine.
    Carnahan RM; Perry PJ
    Am J Psychiatry; 2005 Jul; 162(7):1391; author reply 1391-2. PubMed ID: 15994736
    [No Abstract]   [Full Text] [Related]  

  • 20. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.